Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Drug Manufacturers — Specialty and Generic

Supernus Pharmaceuticals, Inc. operates as a specialty pharmaceutical company. The Company develops and markets proprietary drugs for the treatment of central nervous system diseases and disorders. Supernus Pharmaceuticals offers portfolio of clinical stage drugs to address neurological and psychological problems such as epilepsy, conduct disorder, Parkinson"s disease, ADHD, and depression.
Website: supernus.com


  • Bad financial results growth rate -44.7% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (17.1%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -4.5% (LTM)
  • Share price is 116.4% higher than minimum and 13.8% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (42.9x vs 19.3x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $1.0 mln (-0.037% of cap.)

Key Financials (Download financials)

Ticker: SUPN
Share price, USD:  (0.0%)49.16
year average price 40.51  


year start price 39.11 2025-02-14

min close price 30.29 2025-04-21

max close price 57.00 2025-11-04

current price 49.16 2026-02-14
Common stocks: 56 552 741

Dividend Yield:  0.0%
FCF Yield LTM: -4.5%
EV / LTM EBITDA: 42.9x
EV / Sales: 3.1x
Margin (EBITDA LTM / Revenue): 7.2%

Target EV / EBITDA (hist percentile): 19.3x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 2 780
Net Debt ($m): -250
EV (Enterprise Value): 2 530
EBITDA LTM (млн $): 59
EV / LTM EBITDA: 42.9x
Price to Book: 2.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-01seekingalpha.com

Supernus: Outlook For 2026 Positive, Upholding Buy Rating

2025-12-15fool.com

Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

2025-11-21globenewswire.com

Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

2025-11-05seekingalpha.com

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript

2025-11-04zacks.com

Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say

2025-11-02defenseworld.net

Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by Cwm LLC

2025-10-27zacks.com

Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?

2025-10-10zacks.com

Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?

2025-09-25zacks.com

Are You Looking for a Top Momentum Pick? Why Supernus Pharmaceuticals (SUPN) is a Great Choice

2025-09-23zacks.com

Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-05 2024-11-04 2024-08-06 2024-05-08 2023-11-08 2023-08-08 2023-05-09 2022-11-09
acceptedDate 2025-11-06 17:01:34 2025-08-05 16:24:41 2025-02-25 16:13:58 2024-11-04 16:19:48 2024-08-06 16:18:50 2024-05-08 16:11:18 2024-02-27 16:14:59 2023-11-08 16:14:55 2023-08-08 16:29:33 2023-05-09 16:16:45 2023-03-09 16:15:30 2022-11-09 17:07:04 2022-04-13 16:06:45 2021-03-08 16:30:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 192M 165M 662M 176M 168M 144M 608M 154M 136M 154M 667M 177M 580M 520M
costOfRevenue 48M 17M 78M 38M 39M 37M 84M 20M 21M 23M 87M 26M 75M 52M
grossProfit 144M 149M 584M 138M 130M 107M 524M 134M 114M 130M 580M 151M 505M 468M
grossProfitRatio 0.748 0.898 0.786 0.771 0.742 0.873 0.844 0.847 0.854
researchAndDevelopmentExpenses 29M 22M 109M 29M 26M 24M 92M 23M 24M 21M 75M 20M 90M 76M
generalAndAdministrativeExpenses 0 28M 247M 15M 27M 27M 237M 26M 27M 28M 109M 27M 105M 66M
sellingAndMarketingExpenses 0 65M 89M 54M 59M 60M 100M 57M 60M 57M 268M 86M 200M 135M
sellingGeneralAndAdministrativeExpenses 180M 94M 336M 70M 86M 87M 336M 83M 87M 86M 377M 112M 305M 201M
otherExpenses -5M 21M 58M 0 16M 0 101M 0 0 20M 82M 21M 23M 18M
operatingExpenses 204M 136M 502M 117M 111M 111M 529M 127M 131M 127M 534M 153M 419M 294M
costAndExpenses 252M 153M 580M 135M 150M 148M 613M 146M 152M 150M 621M 178M 494M 347M
interestIncome 2M 5M 16M 4M 4M 3M 10M 2M 1M 5M 22M 3M 11M 19M
interestExpense 0 0 0 0 0 0 2M 0 910 000 2M 7M 2M 23M 24M
depreciationAndAmortization 21M 21M 80M 20M 21M 21M 85M 22M 21M 20M 86M 21M 33M 18M
ebitda -37M 33M 178M 65M 39M 17M 90M 31M 5M 29M 153M 22M 129M 211M
ebitdaratio -0.191 0.202 0.37 0.231 0.115 0.203 0.039 0.188 0.126
operatingIncome -60M 12M 82M 41M 18M -4M -5M 8M -18M 9M 46M 2M 86M 174M
operatingIncomeRatio -0.314 0.073 0.232 0.108 -0.03 0.053 -0.13 0.058 0.01
totalOtherIncomeExpensesNet 2M 5M 16M 4M 4M 4M 8M 456 000 -790 000 142 000 15M -2M -13M -5M
incomeBeforeTax -58M 17M 98M 45M 26M 243 000 3M 10M -17M 9M 61M -444 000 73M 169M
incomeBeforeTaxRatio -0.302 0.101 0.256 0.156 0.002 0.064 -0.126 0.059 -0.003
incomeTaxExpense -13M -6M 24M 6M 6M 119 000 1M 26M -16M -8M 32 000 -2M 20M 42M
netIncome -45M 22M 74M 38M 20M 124 000 1M -16M -831 000 17M 61M 2M 53M 127M
netIncomeRatio -0.235 0.136 0.219 0.118 0.001 -0.104 -0.006 0.11 0.01
eps -0.8 0.4 1.34 0.7 0.36 0.002 0.024 -0.29 -0.015 0.31 1.13 0.03 1.01 2.41
epsdiluted -0.8 0.4 0.69 0.36 0.002 -0.29 -0.015 0.29 0.03
weightedAverageShsOut 56M 56M 55M 55M 55M 55M 55M 55M 55M 54M 54M 54M 53M 53M
weightedAverageShsOutDil 57M 57M 56M 56M 56M 56M 56M 55M 55M 62M 62M 55M 54M 54M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-02-27 2023-03-09 2022-04-13 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 16M 8M 15M -13M -5M
ebit 98M 5M 68M 97M 192M
nonOperatingIncomeExcludingInterest -16M -10M -22M -11M -19M
netIncomeFromContinuingOperations 74M 1M 61M 53M 127M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 -4M 0 0
bottomLineNetIncome 74M 1M 64M 53M 127M
epsDiluted 1.32 0.024 1.04 0.98 2.36

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-05 2024-11-04 2024-08-06 2024-05-08 2023-11-08 2023-08-08 2023-05-09 2022-11-09
acceptedDate 2025-11-06 17:01:34 2025-08-05 16:24:41 2025-02-25 16:13:58 2024-11-04 16:19:48 2024-08-06 16:18:50 2024-05-08 16:11:18 2024-02-27 16:14:59 2023-11-08 16:14:55 2023-08-08 16:29:33 2023-05-09 16:16:45 2023-03-09 16:15:30 2022-11-09 17:07:04 2022-04-13 16:06:45 2021-03-08 16:30:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 151M 145M 69M 32M 52M 63M 75M 95M 25M 58M 93M 111M 203M 289M
shortTermInvestments 130M 378M 384M 372M 295M 234M 180M 105M 127M 170M 368M 280M 136M 134M
cashAndShortTermInvestments 281M 523M 454M 403M 347M 298M 255M 200M 152M 229M 461M 392M 340M 423M
netReceivables 171M 141M 142M 145M 152M 148M 144M 142M 137M 144M 165M 164M 149M 141M
inventory 79M 44M 54M 64M 68M 75M 77M 83M 91M 91M 92M 83M 86M 48M
otherCurrentAssets 62M 31M 36M 27M 23M 24M 17M 24M 45M 16M 16M 25M 0 0
totalCurrentAssets 594M 739M 686M 640M 591M 544M 493M 449M 424M 883M 734M 664M 602M 630M
propertyPlantEquipmentNet 11M 11M 12M 12M 40M 43M 14M 14M 14M 15M 15M 16M 17M 38M
goodwill 119M 117M 117M 117M 117M 117M 117M 117M 117M 117M 117M 117M 118M 78M
intangibleAssets 623M 481M 522M 540M 560M 580M 600M 641M 662M 682M 702M 723M 785M 364M
goodwillAndIntangibleAssets 743M 598M 639M 657M 677M 697M 717M 758M 779M 800M 819M 840M 902M 442M
longTermInvestments 0 0 0 0 -11M 12M 17M 25M 37M 54M 94M 132M 119M 350M
taxAssets 0 6M 0 7M 11M 20M 0 35M 44M 50M 0 0 0 0
otherNonCurrentAssets 73M 28M 32M 26M 8M -11M 38M 4M -6M -9M 40M 41M 49M 43M
totalNonCurrentAssets 826M 644M 682M 703M 725M 760M 785M 836M 870M 908M 968M 1 029M 1 088M 874M
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0 0 0
totalAssets 1 420M 1 382M 1 368M 1 343M 1 316M 1 304M 1 278M 1 285M 1 293M 1 792M 1 703M 1 693M 1 689M 1 504M
accountPayables 109M 8M 5M 6M 5M 14M 2M 3M 4M 95M 11M 110M 9M 6M
shortTermDebt 0 7M 0 9M 10M 9M 0 8M 8M 481M 402M 401M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 229M 219M 0 0 58M 0 0
otherCurrentLiabilities 222M 271M 69M 276M 294M 291M 77M 47M 21M 155M 55M 156M 93M 56M
totalCurrentLiabilities 331M 286M 292M 292M 309M 315M 290M 288M 253M 732M 688M 726M 315M 245M
longTermDebt 31M 24M 0 29M 30M 33M 0 34M 34M 37M 0 36M 379M 362M
deferredRevenueNonCurrent 0 0 0 0 -1 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 5M 0 11M 20M 25M 35M 44M 50M 50M 58M 85M 35M
otherNonCurrentLiabilities 8M 8M 8M 15M 8M 8M 8M 16M 42M 62M 43M -456M 52M 68M
totalNonCurrentLiabilities 39M 32M 40M 44M 50M 60M 66M 85M 121M 148M 128M 114M 558M 514M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 31M 32M 34M 38M 40M 33M 42M 42M 42M 37M 43M 36M 48M 53M
totalLiabilities 370M 319M 332M 336M 358M 375M 356M 373M 373M 880M 816M 840M 873M 759M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 57 000 56 000 56 000 55 000 55 000 55 000 55 000 55 000 55 000 54 000 54 000 54 000 53 000 53 000
retainedEarnings 522M 567M 556M 541M 503M 483M 483M 481M 497M 498M 481M 456M 380M 326M
accumulatedOtherComprehensiveIncomeLoss -71 000 -200 000 -189 000 78 000 -372 000 -534 000 -593 000 -1M -2M -2M -3M -4M 2M 9M
othertotalStockholdersEquity 528M 497M 466M 455M 447M 432M 424M 416M 401M
totalStockholdersEquity 1 050M 1 064M 1 036M 1 007M 957M 929M 922M 912M 920M 912M 886M 853M 816M 745M
totalEquity 1 050M 1 064M 1 036M 1 007M 957M 929M 922M 912M 920M 912M 886M 853M 816M 745M
totalLiabilitiesAndStockholdersEquity 1 420M 1 382M 1 343M 1 316M 1 304M 1 285M 1 293M 1 792M 1 693M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 420M 1 382M 1 368M 1 343M 1 316M 1 304M 1 278M 1 285M 1 293M 1 792M 1 703M 1 693M 1 689M 1 504M
totalInvestments 130M 378M 384M 372M 295M 246M 196M 130M 164M 224M 462M 412M 255M 484M
totalDebt 31M 32M 34M 38M 40M 42M 42M 42M 42M 517M 445M 437M 427M 414M
netDebt -120M -113M -35M 6M -12M -21M -34M -53M 17M 459M 352M 326M 224M 126M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-02-27 2023-03-09 2022-04-13 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 142M 144M 165M 149M 141M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 27M 19M
totalPayables 5M 2M 11M 9M 6M
otherPayables 0 0 0 0 0
accruedExpenses 212M 203M 214M 207M 179M
capitalLeaseObligationsCurrent 7M 8M 7M 6M 4M
capitalLeaseObligationsNonCurrent 27M 33M 36M 41M 49M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 479M 439M 408M 434M 409M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN SUPN
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-06 2025-08-05 2024-11-04 2024-08-06 2024-05-08 2023-11-08 2023-08-08 2023-05-09 2022-11-09
acceptedDate 2025-11-06 17:01:34 2025-08-05 16:24:41 2025-02-25 16:13:58 2024-11-04 16:19:48 2024-08-06 16:18:50 2024-05-08 16:11:18 2024-02-27 16:14:59 2023-11-08 16:14:55 2023-08-08 16:29:33 2023-05-09 16:16:45 2023-03-09 16:15:30 2022-11-09 17:07:04 2022-04-13 16:06:45 2021-03-08 16:30:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -45M 22M 74M 38M 20M 124 000 1M -16M -831 000 17M 61M 2M 53M 127M
depreciationAndAmortization 25M 21M 80M 20M 21M 21M 85M 22M 21M 21M 86M 22M 33M 18M
deferredIncomeTax -3M -7M -20M -6M -8M -5M -26M -9M -6M -435 000 -26M -3M -5M 568 000
stockBasedCompensation 8M 8M 28M 8M 7M 6M 27M 8M 6M 6M 18M 5M 18M 17M
changeInWorkingCapital -49M 11M -2M -8M -3M 14M -9M 30M -46M 5M -24M -24M 4M -37M
accountsReceivables -7M 5M 2M 7M -5M -4M 19M -5M 4M 22M -16M -6M 4M -35M
inventory -13M 5M 16M 5M 6M 2M 6M 7M -4M -2M -18M -8M -15M -10M
accountsPayables -22M -6M -15M -12M -13M 10M -36M -6M -19M -11M -19M -24M 18M 8M
otherWorkingCapital -8M 8M -5M -8M 9M 5M 2M 34M -27M -10M 29M 14M -4M -56 000
otherNonCashItems 3M 3M 12M 2M 59M 42M 33M 2M 7M 288 000 4M 12M 25M 13M
netCashProvidedByOperatingActivities -62M 59M 172M 54M 36M 38M 111M 36M -19M 49M 117M 14M 127M 138M
investmentsInPropertyPlantAndEquipment -129 000 -455 000 -725 000 -200 000 -64 000 -248 000 -551 000 -150 000 -159 000 -278 000 -412 000 -147 000 -2M -3M
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 -14 000 0 -312M -314M
purchasesOfInvestments -127M -141M -688M -225M -124M -194M -102M 0 0 0 -407M -134M -312M -96M
salesMaturitiesOfInvestments 469M 110M 499M 148M 75M 142M 371M 35M 60M 240M 191M 52M 531M 378M
otherInvestingActivites -293M 0 9000 -49M -51M 35M 0 0 0
netCashUsedForInvestingActivites 49M -31M -77M -49M -52M 35M 60M 240M -82M
debtRepayment 0 0 0 0 0 0 -481M -15M 0
commonStockIssued 24M 3M 3M 2M 3M -230 000 2M 2M 6M
commonStockRepurchased 0 0 0 0 0 -1M 0 -230 000 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -3M -2M -387 000 -1000 -1M 230 000 0 93M 0
netCashUsedProvidedByFinancingActivities 21M 935 000 3M 2M 2M -230 000 -479M 80M 6M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 8M 29M -6M -20M -11M -12M -18M 70M -437M 369M -110M -62M -85M 107M
cashAtEndOfPeriod 153M 145M 69M 32M 52M 63M 75M 95M 25M 462M 93M 111M 203M 289M
cashAtBeginningOfPeriod 145M 116M 75M 52M 63M 75M 93M 25M 462M 93M 203M 173M 289M 181M
operatingCashFlow -62M 59M 172M 54M 36M 38M 111M 36M -19M 49M 117M 14M 127M 138M
capitalExpenditure -129 000 -455 000 -725 000 -200 000 -64 000 -248 000 -551 000 -150 000 -159 000 -278 000 -412 000 -147 000 -2M -3M
freeCashFlow -62M 58M 171M 53M 36M 38M 111M 36M -19M 49M 116M 14M 125M 135M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-25 2024-02-27 2023-03-09 2022-04-13 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 9000 0 14 000 13M -241 000
netCashProvidedByInvestingActivities -190M 269M -217M -82M -35M
netDebtIssuance 0 -403M 0 -138M -802 000
longTermNetDebtIssuance 0 0 0 -138M -802 000
shortTermNetDebtIssuance 0 -403M 0 0 0
netStockIssuance 15M 7M 12M 7M 4M
netCommonStockIssuance 15M 7M 12M 7M 4M
commonStockIssuance 15M 7M 12M 7M 4M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -3M -2M -23M 0 0
netCashProvidedByFinancingActivities 12M -398M -10M -130M 4M
incomeTaxesPaid 53M 37M 16M 25M 45M
interestPaid 0 2M 3M 3M 3M

Earning call transcript

2025 q3
2025-11-05 ET (fiscal 2025 q3)
2025 q2
2025-08-05 ET (fiscal 2025 q2)
2025 q1
2025-05-06 ET (fiscal 2025 q1)
2024 q4
2025-02-25 ET (fiscal 2024 q4)
2024 q3
2024-11-04 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-27 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-09 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-11-04 16:17 ET
Supernus Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-04 16:17 ET
Supernus Pharmaceuticals reported for 2025 q3
SEC form 10
2025-08-05 20:24 ET
Supernus Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-05 20:18 ET
Supernus Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-05 20:18 ET
Supernus Pharmaceuticals reported for 2025 q2
SEC form 8
2025-07-22 00:00 ET
Supernus Pharmaceuticals published news for 2025 q2
SEC form 8
2025-07-22 00:00 ET
Supernus Pharmaceuticals published news for 2025 q2
SEC form 8
2025-06-17 20:40 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-16 12:34 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-16 12:34 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-16 12:34 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-16 12:34 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-28 20:09 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-28 20:09 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-06 20:20 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-06 20:14 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-06 20:14 ET
Supernus Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-06 00:00 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-23 00:00 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 8
2025-04-23 00:00 ET
Supernus Pharmaceuticals published news for 2025 q1
SEC form 10
2025-02-25 21:13 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-25 00:00 ET
Supernus Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-18 21:35 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-18 21:35 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-11 00:00 ET
Supernus Pharmaceuticals published news for 2024 q4
SEC form 10
2024-11-04 16:19 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-04 16:13 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-04 16:13 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 8
2024-10-21 00:00 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 8
2024-10-21 00:00 ET
Supernus Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-06 16:18 ET
Supernus Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-06 16:16 ET
Supernus Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-06 16:16 ET
Supernus Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-06 00:00 ET
Supernus Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-23 00:00 ET
Supernus Pharmaceuticals published news for 2024 q2
SEC form 8
2024-07-23 00:00 ET
Supernus Pharmaceuticals published news for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Supernus Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Supernus Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Supernus Pharmaceuticals reported for 2024 q1
SEC form 8
2024-04-24 00:00 ET
Supernus Pharmaceuticals published news for 2024 q1
SEC form 8
2024-04-24 00:00 ET
Supernus Pharmaceuticals published news for 2024 q1
SEC form 8
2024-02-27 16:15 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-27 16:15 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-27 16:14 ET
Supernus Pharmaceuticals reported for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-13 00:00 ET
Supernus Pharmaceuticals published news for 2023 q4
SEC form 10
2023-11-08 16:14 ET
Supernus Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-08 16:10 ET
Supernus Pharmaceuticals published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Supernus Pharmaceuticals published news for 2023 q3
SEC form 8
2023-10-25 00:00 ET
Supernus Pharmaceuticals published news for 2023 q3
SEC form 10
2023-08-08 16:29 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 6
2023-08-08 16:19 ET
Supernus Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 6
2023-07-24 16:08 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 8
2023-07-24 00:00 ET
Supernus Pharmaceuticals published news for 2023 q2
SEC form 6
2023-06-23 16:03 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 6
2023-06-20 07:06 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 8
2023-04-26 00:00 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 6
2023-04-03 16:10 ET
Supernus Pharmaceuticals published news for 2023 q1
SEC form 10
2023-03-09 16:15 ET
Supernus Pharmaceuticals reported for 2022 q4
SEC form 10
2023-03-09 00:00 ET
Supernus Pharmaceuticals reported for 2022 q4
SEC form 6
2023-03-02 16:19 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 6
2023-03-01 17:01 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-28 17:03 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Supernus Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-14 17:03 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 8
2023-02-10 00:00 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 6
2023-02-09 18:19 ET
Supernus Pharmaceuticals published news for 2022 q4
SEC form 10
2022-11-09 17:07 ET
Supernus Pharmaceuticals reported for 2022 q3
SEC form 10
2022-11-09 00:00 ET
Supernus Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-08 17:09 ET
Supernus Pharmaceuticals published news for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Supernus Pharmaceuticals reported for 2022 q3
SEC form 6
2022-10-25 16:34 ET
Supernus Pharmaceuticals published news for 2022 q3
SEC form 8
2022-10-25 00:00 ET
Supernus Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-11 16:32 ET
Supernus Pharmaceuticals published news for 2022 q3
SEC form 10
2022-08-08 16:24 ET
Supernus Pharmaceuticals reported for 2022 q2
SEC form 10
2022-08-08 00:00 ET
Supernus Pharmaceuticals reported for 2022 q2
SEC form 6
2022-08-04 17:07 ET
Supernus Pharmaceuticals published news for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Supernus Pharmaceuticals reported for 2022 q2
SEC form 6
2022-07-26 16:42 ET
Supernus Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-17 16:31 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-06-09 08:54 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-12 17:15 ET
Supernus Pharmaceuticals reported for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Supernus Pharmaceuticals reported for 2022 q1
SEC form 6
2022-05-10 17:29 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-09 17:22 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Supernus Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-03 18:12 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-03 16:42 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-02 16:01 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-13 16:18 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 10
2022-04-13 16:06 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 10
2022-04-13 00:00 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 8
2022-04-13 00:00 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-04 18:19 ET
Supernus Pharmaceuticals published news for 2022 q1
SEC form 6
2022-03-21 16:07 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-01 17:17 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-28 17:00 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:29 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:27 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:26 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:26 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:24 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:24 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:24 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:23 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:22 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-24 21:22 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-22 16:58 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 8
2022-02-22 00:00 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-10 17:17 ET
Supernus Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-08 08:31 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-24 20:59 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-24 09:21 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 16:11 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-03 17:56 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 8
2021-10-28 00:00 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-27 18:21 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-12 07:53 ET
Supernus Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-02 19:05 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-24 17:13 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-06 12:52 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-06 00:00 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-04 17:28 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-29 16:31 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-22 16:41 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 8
2021-07-22 00:00 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-19 16:36 ET
Supernus Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-25 08:12 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-16 09:04 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-26 16:35 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-25 16:58 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-24 16:44 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-19 16:02 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-07 16:52 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-05 16:58 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-04 17:40 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-30 14:31 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 8
2021-04-28 00:00 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-27 17:55 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-02 17:45 ET
Supernus Pharmaceuticals published news for 2021 q1
SEC form 10
2021-03-08 16:30 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-01 16:02 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-25 18:44 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-24 17:27 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-24 12:48 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:55 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:54 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:53 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:51 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:49 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:49 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:48 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:47 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:46 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-23 18:46 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-22 17:14 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-08 19:43 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-04 19:59 ET
Supernus Pharmaceuticals published news for 2020 q4
SEC form 6
2020-12-22 20:38 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-12-15 20:20 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-19 17:27 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-09 18:49 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 10
2020-11-06 15:31 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-03 17:40 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-27 17:33 ET
Supernus Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-05 16:05 ET
Supernus Pharmaceuticals published news for 2020 q3